BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17408400)

  • 1. Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas.
    Lee JJ; Kim DH; Lee NY; Sohn SK; Kim JG; Kim HJ; Do YR; Park YH
    Br J Haematol; 2007 May; 137(4):329-36. PubMed ID: 17408400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study.
    Kube D; Hua TD; von Bonin F; Schoof N; Zeynalova S; Klöss M; Gocht D; Potthoff B; Tzvetkov M; Brockmöller J; Löffler M; Pfreundschuh M; Trümper L
    Clin Cancer Res; 2008 Jun; 14(12):3777-84. PubMed ID: 18559596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
    Park YH; Sohn SK; Kim JG; Lee MH; Song HS; Kim MK; Jung JS; Lee JJ; Kim HJ; Kim DH
    Clin Cancer Res; 2009 Mar; 15(6):2107-15. PubMed ID: 19276283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study.
    Sung HJ; Kim SJ; Seo HY; Sul HR; Choi JG; Choi IK; Park KH; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Br J Haematol; 2006 Jul; 134(1):45-53. PubMed ID: 16803566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation.
    Seo KW; Kim DH; Sohn SK; Lee NY; Chang HH; Kim SW; Jeon SB; Baek JH; Kim JG; Suh JS; Lee KB
    Bone Marrow Transplant; 2005 Dec; 36(12):1089-95. PubMed ID: 16247433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma.
    Møller MB; Gerdes AM; Skjødt K; Mortensen LS; Pedersen NT
    Clin Cancer Res; 1999 May; 5(5):1085-91. PubMed ID: 10353742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma.
    Fernberg P; Chang ET; Duvefelt K; Hjalgrim H; Eloranta S; Sørensen KM; Porwit A; Humphreys K; Melbye M; Ekström Smedby K
    Cancer Causes Control; 2010 May; 21(5):759-69. PubMed ID: 20087644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms.
    Domingo-Domènech E; Benavente Y; González-Barca E; Montalban C; Gumà J; Bosch R; Wang SS; Lan Q; Whitby D; Fernández de Sevilla A; Rothman N; de Sanjosé S
    Haematologica; 2007 Nov; 92(11):1475-81. PubMed ID: 18024395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Münster Trial NHL-BFM 95.
    Seidemann K; Zimmermann M; Book M; Meyer U; Burkhardt B; Welte K; Reiter A; Stanulla M
    J Clin Oncol; 2005 Nov; 23(33):8414-21. PubMed ID: 16293872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis.
    Wieczorek S; Hellmich B; Arning L; Moosig F; Lamprecht P; Gross WL; Epplen JT
    Arthritis Rheum; 2008 Jun; 58(6):1839-48. PubMed ID: 18512809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma.
    Sakata K; Satoh M; Someya M; Asanuma H; Nagakura H; Oouchi A; Nakata K; Kogawa K; Koito K; Hareyama M; Himi T
    Cancer; 2004 Jan; 100(2):356-65. PubMed ID: 14716772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma.
    Kim HN; Lee IK; Kim YK; Tran HT; Yang DH; Lee JJ; Shin MH; Park KS; Shin MG; Choi JS; Kim HJ
    Br J Haematol; 2008 Feb; 140(3):287-94. PubMed ID: 18042267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The polymorphisms of interleukin-10 gene influence the prognosis of patients with advanced melanoma.
    Vuoristo MS
    Cancer Genet Cytogenet; 2007 Jul; 176(1):54-7. PubMed ID: 17574964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
    Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
    J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-10 haplotype associated with total serum IgE in atopic dermatitis patients.
    Shin HD; Park BL; Kim LH; Kim JS; Kim JW
    Allergy; 2005 Sep; 60(9):1146-51. PubMed ID: 16076299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma.
    Heemann C; Kreuz M; Stoller I; Schoof N; von Bonin F; Ziepert M; Löffler M; Jung W; Pfreundschuh M; Trümper L; Kube D
    Clin Cancer Res; 2012 Jul; 18(13):3637-47. PubMed ID: 22573350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.
    Paiva M; Marques H; Martins A; Ferreira P; Catarino R; Medeiros R
    Cancer Genet Cytogenet; 2008 May; 183(1):35-40. PubMed ID: 18474295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma.
    Bogunia-Kubik K; Mazur G; Wróbel T; Kuliczkowski K; Lange A
    Tissue Antigens; 2008 Feb; 71(2):146-50. PubMed ID: 18201362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF-beta1 gene polymorphisms influence the course of the disease in non-Hodgkin's lymphoma patients.
    Mazur G; Bogunia-Kubik K; Wrobel T; Kuliczkowski K; Lange A
    Cytokine; 2006 Feb; 33(3):145-9. PubMed ID: 16524740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.